Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC

• Published in: Cell reports (Cambridge) Vol. 44; no. 4; p. 115543
• Main Authors: Wang, Qian, Guo, Yicheng, Mellis, Ian A., Wu, Madeline, Mohri, Hiroshi, Gherasim, Carmen, Valdez, Riccardo, Purpura, Lawrence J., Yin, Michael T., Gordon, Aubree, Ho, David D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 22.04.2025; Cell Press; Elsevier
• Subjects: ACE2 inhibition; Angiotensin-Converting Enzyme 2 - immunology; Angiotensin-Converting Enzyme 2 - metabolism; Animals; Antibodies, Monoclonal - immunology; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; antibody evasion; COVID-19 - immunology; COVID-19 - virology; CP: Immunology; CP: Microbiology; Humans; JN.1 subvariants; KP.3.1.1; monoclonal antibodies; mRNA vaccines; Mutation; Neutralization Tests; SARS-CoV-2; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; serum neutralization; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; XEC; CP: Immunology; ACE2 inhibition; SARS-CoV-2; XEC; CP: Microbiology; mRNA vaccines; JN.1 subvariants; antibody evasion; serum neutralization; KP.3.1.1; monoclonal antibodies

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread, and it remains critical to understand the functional consequences of mutations in dominant viral variants. The recombinant JN.1 subvariant XEC recently replaced KP.3.1.1 to become the most prevalent subvaria...